US News topics
headline news | recent news | latest news | market news | recent topics | stock topics
Country: US | UK | AU | HK | SG | MY
Market news - chevrons indicate local prediction, arrows show global predictions, circles show importance
Local topics
Nevada launches contact tracing app to anonymously alert of possible COVID-19 exposures - carsonnow org CZR - 06:45 Sun link | |
Minera Panamá Requests Unblocking Access To Mine For Entry Of Environmental Supplies - menafn MAIFF - 5h ago link | |
Critical Survey: Pulmonx (NASDAQ:LUNG) versus Profound Medical (NASDAQ:PROF) - modernreaders PROF - 03:00 Sun link | |
Climate activists outnumbered by fossil fuel execs at Cop28 as space for protest shrinks - enviweb cz FOSL - 09:15 Sun link | |
Climate activists outnumbered by fossil fuel execs at Cop28 as space for protest shrinks - yahoo FOSL - 09:00 Sun link | |
Weight loss injections and suicide: Investigating the connection - jpost LLY - 20:00 Sun link | |
BNP Paribas Initiates Coverage on IDEXX Laboratories (NASDAQ:IDXX) - tickerreport IDXX - 12:45 Sun link | |
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease - joplinglobe INCY - 2h ago link | |
Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis - valdostadailytimes ALXN - 54m ago link | |
Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis - financialpost PCDAF - 3h ago link | |
Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis - lelezard ALXN - 54m ago link | |
Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis - joplinglobe ALXN - 2h ago link | |
Public meeting, safety plan, state oversight required before implosion of Springdale power plant - triblive CHRA - 2h ago link | |
Consumer product agency issues warning on small magnetic balls linked to deaths - netscape NYT - 08:30 Sun link | |
Consumer product agency issues warning on small magnetic balls linked to deaths - springfieldnewssun NYT - 02:15 Sun link | |
XRP Bulls on Alert as Analyst Signals Bullish Momentum, Targets $2 and Beyond - biztoc GBTC - 13:15 Sun link | |
Profound Medical (NASDAQ:PROF) versus Pulmonx (NASDAQ:LUNG) Head to Head Review - etfdailynews PROF - 03:15 Sun link | |
Contrasting Gossamer Bio (NASDAQ:GOSS) & ContraFect (NASDAQ:CFRX) - etfdailynews CFRX - 05:15 Sun link | |
EQS-News: MorphoSys' Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study - businessinsider MOR - 2h ago link | |
Head-To-Head Analysis: Profound Medical (NASDAQ:PROF) vs. Hypertension Diagnostics (OTCMKTS:HDII) - dailypolitical PROF - 18:30 Sun link |